Compound: Alvimopan
SMILES: O=C(NCC(=O)O)[C@H](CN1C[C@@H]([C@@](c2cc(O)ccc2)(C)CC1)C)Cc3ccccc3
InChIKey: UPNUIXSCZBYVBB-JVFUWBCBSA-N
Synonyms: Alvimopan, 156053-89-3, Alvimopan anhydrous, Entereg, Adl 8-2698, anhydrous alvimopan, LY246736, trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, LY-246736, Q153V49P3Z, Glycine, N-[(2S)-2-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, LY-246736 dihydrate, DTXSID60166035, ADL-8-2698, 2-[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanamido]acetic acid, Glycine, N-((2S)-2-(((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl)-1-oxo-3-phenylpropyl)-, alvimopanum, 2-(((2S)-2-(((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)methyl)-3-phenylpropanoyl)amino)acetic acid, 2-((2S)-2-benzyl-3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanamido)acetic acid, 2-[[(2S)-2-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl]-3-phenylpropanoyl]amino]acetic acid, ADL8-2698, RefChem:111766, DTXCID7088526, A06AH02, LY-246376, 110-129-5, (((2S)-2-(((3R,4R)-4-(3-Hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)methyl)-3-phenylpropanoyl)amino)acetic acid dihydrate, 677C126AET, Alvimopan [INN], 2-((S)-2-benzyl-3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanamido)acetic acid, LY 246736, MFCD09838268, 145590-44-9, 2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid, N-[(2S)-2-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl}-3-phenylpropanoyl]glycine, UNII-Q153V49P3Z, Glycine, N-[(2S)-2-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-; Glycine, N-[2-[[4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, [3R-[1(S*),3a,4a]]-; ADL 8-2698; Alvimopan; Entereg; LY 246736, N-((2S)-2-(((3R,4R)-4-(3-HYDROXYPHENYL)-3,4-DIMETHYL-1-PIPERIDINYL)METHYL)-1-OXO-3-PHENYLPROPYL)GLYCINE, N-[(2S)-2-[[(3R,4R)-4-(3-Hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]glycine, ALVIMOPAN [MI], ALVIMOPAN [MART.], ALVIMOPAN [WHO-DD], SCHEMBL49578, CHEMBL270190, GTPL7471, orb1309266, Alvimopan, >=98% (HPLC), HSDB 7704, CHEBI:135686, GLXC-08199, HMS3886B09, ANHYDROUS ALVIMOPAN [MART.], BDBM50088381, EBC-27050, s5935, AKOS015896476, CS-0536, DB06274, FA17336, ((S)-2-benzyl-3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanoyl)glycine, NCGC00378640-01, NCGC00378640-02, NCGC00378640-03, AS-35088, HY-13243, NS00069226, ADL 8-2698;LY 246736, SBI-0654641.0001, EN300-7393122, SR-01000945029, Q4738021, SR-01000945029-1, BRD-K07857022-002-01-1, (((2S)-2-(((3R,4R)-4-(3-HYDROXYPHENYL)-3,4-DIMETHYLPIPERIDIN-1-YL)METHYL)-3-PHENYLPROPANOYL)AMINO)ACETIC ACID, ((2(S)-((4(R)-(3-HYDROXYPHENYL)-3(R),4-DIMETHYL-1-PIPERIDINYL)METHYL)-1-OXO-3-PHENYLPROPYL)AMINO)ACETIC ACID, 2-((S)-2-benzyl-3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)propanamido)aceticacid, 2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidyl]propanoyl]amino]acetic acid, GLYCINE, N-(2-((4-(3-HYDROXYPHENYL)-3,4-DIMETHYL-1-PIPERIDINYL)METHYL)-1-OXO-3-PHENYLPROPYL)-, (3R-((S*),3.ALPHA.,4.ALPHA.))-, NG0
Theoretical properties:
molecular_formula: C25H32N2O4
molecular_weight: 424.5 g/mol
exact_mass: 424.23620751 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 3
hydrogen_bond_acceptor_count: 5
rotatable_bond_count: 8
heavy_atom_count: 31
topological_polar_surface_area: 89.9 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
solubility: <0.1 mg/mL
Descriptions:
pubchem: Alvimopan is a peptide.
chembl: ALVIMOPAN is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Alvimopan (trade name Entereg) is a drug which behaves as a peripherally acting μ-opioid receptor antagonist. With the limited ability to cross the blood–brain barrier and reach the μ-opioid receptors of the central nervous system, the clinically undesirable effects of centrally acting opioid antagonists (like reversal of opioid-mediated analgesia) are avoided without affecting the intended blockade of μ-opioid receptors in the gastrointestinal tract. It is currently only Food and Drug Administration approved for the treatment of postoperative ileus which it received in May 2008.